Boulding Mark Elliott

Avg. Two Year Performance

No purchase track record
24% Avg. Sale Return
11% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return----------
Purchase Success Rate----------
Average Sale Return4%9%14%22%24%
Sale Success Rate2 of 113 of 112 of 112 of 113 of 11

Ptc Therapeutics, Inc.

Drugs » Biotechnology

Exec. VP and CLO:

Holdings: 92.39K shares

Sentiment

Insider Trading Sentiment: Accumulate

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--